ClinicalTrials.gg
CompletedNCT00442325ACTFAST 2Updated Feb 18, 2021

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

A Phase 4 interventional study of Atorvastatin (Lipitor) in Coronary Arteriosclerosis, Diabetes Mellitus, Type 2 and Cerebrovascular Accident, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
595
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.

Enrollment
4th of 33
595 · median 120
Started
2003
with 4 others
Phase 4
19 of 33
1 open now
Registered
6th of 33
by date
Lead sponsor
3 of 33
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 4th largest by enrollment, is one of 5 that started in 2003, is one of 19 in phase 4, and was the 6th registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing atorvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)

03

Conditions studied

  • Coronary Arteriosclerosis
  • Diabetes Mellitus, Type 2
  • Cerebrovascular Accident
  • Dyslipidemia
  • Peripheral Vascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
  • Triglycerides up to 600 mg/dL.
  • History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation, use of high statin doses (>40mg) at baseline, liver or renal problems
  • Use of other drugs that would interfere with evaluation of efficacy or cause safety problems
  • Uncontrolled hypertension, diabetes or hypothyroidism
  • Recent cardiac event of procedure
  • High baseline CPK levels
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
595 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.

Secondary outcomes

  1. Percentage of subjects achieving:

  2. LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.

  3. Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.

  4. Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.

  5. Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.

  6. LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata.

  7. LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%).

  8. The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol

07

Study locations

33 sites
  • Pfizer Investigational Site
    Ioannina, Greece
  • Pfizer Investigational Site
    Kallithea, Athens, Greece
  • Pfizer Investigational Site
    Pireaus, Greece
  • Pfizer Investigational Site
    Thessaloniki, Greece
  • Pfizer Investigational Site
    Budapest, Hungary
  • Pfizer Investigational Site
    Gyula, Hungary
  • Pfizer Investigational Site
    Kecskemet, Hungary
  • Pfizer Investigational Site
    Nyíregyháza, Hungary
  • Pfizer Investigational Site
    Szekszárd, Hungary
  • Pfizer Investigational Site
    Tullamore, CO. Offlay, Ireland
  • Pfizer Investigational Site
    Tallaght, Dublin, Ireland
  • Pfizer Investigational Site
    Gorey, Wexford, Ireland
  • Pfizer Investigational Site
    Cork, Ireland
  • Pfizer Investigational Site
    Dublin 8, Ireland
  • Pfizer Investigational Site
    Dublin, Ireland
  • Pfizer Investigational Site
    Galway, Ireland
  • Pfizer Investigational Site
    Czestochowa, Poland
  • Pfizer Investigational Site
    Poznan, Poland
  • Pfizer Investigational Site
    Warszawa, Poland
  • Pfizer Investigational Site
    Wroclaw, Poland
  • Pfizer Investigational Site
    Zabrze, Poland
  • Pfizer Investigational Site
    Aveiro, Portugal
  • Pfizer Investigational Site
    Lisboa, Portugal
  • Pfizer Investigational Site
    Porto, Portugal
  • Pfizer Investigational Site
    Vila Franca de Xira, Portugal
  • Pfizer Investigational Site
    Moscow, Russian Federation
  • Pfizer Investigational Site
    Bratislava, Slovakia
  • Pfizer Investigational Site
    Kosice, Slovakia
  • Pfizer Investigational Site
    Bern, Switzerland
  • Pfizer Investigational Site
    Genève, Switzerland
  • Pfizer Investigational Site
    Mendrisio, Switzerland
  • Pfizer Investigational Site
    Zürich, Switzerland
  • Pfizer Investigational Site
08

References and documents

Publications

  • Farsang C, Athyros V, Gaw A; ACTFAST-2 investigators and Steering Committee members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007 Aug;23(8):1945-56. doi: 10.1185/030079907X223242. PubMed 17626713 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 1, 2007
Start
Jan 2003
Completion
Feb 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00442325
Responsible party
Sponsor
First posted
Mar 1, 2007
Start date
Jan 2003
Completion
Feb 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion